| Drug |
Phase |
Company (Institution) |
Condition Assessment |
ClinicalTrials.gov Identifier |
Reference for Results |
| Tolvaptan (Vasopressin V2 Receptor Antagonist) |
TEMPO 2/4 TEMPO 3/4 |
International (Otsuka Pharma) |
ADPKD Kidney Volume |
NCT00413777 NCT00428948 |
57 |
| Sirolimus (mTOR inhibitor) |
Phase 3 SUISSE Study |
University of Zurich |
ADPKD Kidney Volume |
NCT00346918 |
42 |
| |
Phase 2 SIRENA Study |
Mario Negri Inst. |
ADPKD Kidney Volume |
NCT00491517 |
41 |
| |
Phase 1-2 |
Cleveland Clinic |
ADPKD GFR |
NCT00286156 |
|
| |
Phase 2-3 |
Mayo Clinic (Wyeth) |
ADPKD Liver Volume |
|
39 |
| Everolimus (mTOR inhibitor) |
Phase 3 |
Multicenter (Novartis) |
ADPKD Kidney Volume |
NCT00414440 |
43 |
| Octreotide (Somatostatin |
Phase 3 |
Mario Negri Inst. |
ADPKD Kidney Volume |
NCT00309283 |
61 |
| Agonist) |
Phase 2-3 |
Mayo Clinic (Novartis) |
ADPKD-PLD Liver / Kidney Volume, eGFR |
NCT00426153 |
60 |
| Lanreotide (Somatostatin
Agonist) |
Phase 2-3 |
Radbound Univ. (Netherlands) |
ADPKD-PLD Liver Volume |
NCT00565097 NCT00771888 |
63 |
| ACE inhibitor / ARBs |
Phase 3 HALT-PKD |
NIDDK |
ADPKD Kidney Volume |
NCT00283686 |
|
| Pravastatin (a statin) |
Phase 3 |
Univ. of Colorado |
ADPKD Kidney Volume |
NCT00456365 |
|
| Tripotolide (polycystin 2
mimic) |
Phase 2 |
Nanjing University |
ADPKD Kidney Volume eGFR |
NCT00801268 |
|
| Bosutinib (kinase inhibitor) |
Phase 2 |
Pfizer |
ADPKD |
NCT01233869 |
|
| Water Intake |
|
Kyorin University |
ADPKD Kidney Volume & GFR |
NCT01348035 |
56 |
